<DOC>
	<DOCNO>NCT00359762</DOCNO>
	<brief_summary>This study assess effect twice-daily subcutaneous injection exenatide versus treatment sulfonylurea ( glimepiride ) long-term glycemic control beta-cell function .</brief_summary>
	<brief_title>Exenatide Versus Glimepiride Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus . Treated diet exercise stable , maximally tolerate dose metformin least 3 month prior screen . HbA1c &gt; =6.5 % &lt; =9.0 % . Body Mass Index ( BMI ) &gt; =25 kg/m^2 &lt; 40 kg/m^2 . Participated interventional medical , surgical , pharmaceutical study within 30 day prior screen . Characteristics contraindicate metformin glimepiride use . Receiving drug directly affect gastrointestinal motility . Receiving chronic ( lasting longer 2 week ) systemic glucocorticoid therapy . Have use prescription drug promote weight loss within 3 month prior screen . Treated longer 2 week follow medication within 3 month prior screen : *insulin ; *thiazolidinediones ; *alphaglucosidase inhibitor ; *sulfonylurea ; *meglitinides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>glimepiride</keyword>
</DOC>